Meghan Trainor GLP-1: What It Would Cost a Non-Celebrity

What Has Meghan Trainor Said About GLP-1 or Weight Loss?

Meghan Trainor has not made a direct, on-record statement confirming GLP-1 use. She has spoken openly about postpartum body image and weight changes in interviews with outlets including People and on her own podcast, "Workin' On It." In a 2023 People interview she described feeling more comfortable in her body after the birth of her sons Riley and Barry, and noted she had "found what works." That phrase has been widely interpreted by fans and entertainment press as a possible reference to medication-assisted weight loss, but it remains inference, not confirmation.

This article treats the GLP-1 angle as unconfirmed and journalistically labels it as such throughout. The clinical and cost sections below apply to any postpartum adult who wants to know what this class of drug actually costs outside a celebrity budget.

How GLP-1 Medications Work

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and increase insulin secretion in a glucose-dependent manner. The net result is significant, sustained caloric reduction without the cardiovascular risks of older appetite suppressants.

The Two Drugs Most Discussed in Celebrity Contexts

Semaglutide 2.4 mg (Wegovy). The FDA approved Wegovy for chronic weight management in June 2021 [1]. In the STEP-1 trial (N=1,961), weekly subcutaneous semaglutide 2.4 mg produced a mean 14.9% reduction in body weight at 68 weeks versus 2.4% with placebo (P<0.001) [2]. Patients must have a BMI ≥30, or ≥27 with at least one weight-related condition such as hypertension or dyslipidemia.

Tirzepatide 15 mg (Zepbound). The FDA approved Zepbound for weight management in November 2023 [3]. SURMOUNT-1 (N=2,539) reported a mean 20.9% weight reduction at 72 weeks with the 15 mg dose versus 3.1% placebo [4]. Tirzepatide is a dual GIP/GLP-1 agonist, giving it a slightly different mechanism and, in trials, a modestly larger effect size than semaglutide.

Why Celebrities Are Presumed to Have an Advantage

Access to these drugs at full celebrity scale typically means direct-pay concierge prescribing, same-week shipment, and no prior-authorization delays. The list price is irrelevant when a business manager absorbs it. For the average patient, each of those friction points, cost, prior auth, supply, represents a real barrier.

The Real Costs: A Line-by-Line Breakdown

Wegovy (Semaglutide 2.4 mg) Pricing

The Novo Nordisk list price for Wegovy is approximately $1,349.02 per four-pen monthly supply as of 2025 [5]. The titration schedule starts at 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. Each dose tier uses the same pen count, so monthly spend is consistent at list price.

With commercial insurance that covers Wegovy, the Novo Nordisk NovoCare savings program can reduce out-of-pocket cost to $0 per month for eligible patients [6]. Without insurance coverage, the same program caps cost at $500 per 28-day supply for qualifying patients. Medicare Part D is legally prohibited from covering weight-loss drugs under current statute, though the Treat and Reduce Obesity Act has been reintroduced in Congress repeatedly.

Zepbound (Tirzepatide) Pricing

Eli Lilly set the Zepbound list price at $1,059.87 per month for the four-pen supply at launch in late 2023 [3]. Lilly's Zepbound Savings Card brings that to $25 per month for commercially insured patients, or $550 per month for uninsured cash-pay patients who enroll directly at zepbound.com.

Lilly also introduced single-dose vials of tirzepatide in 2024 at prices ranging from $349 to $499 per month depending on dose, specifically to broaden access for cash-pay patients [7].

Compounded Semaglutide

When FDA-approved branded versions faced supply shortages, the FDA placed semaglutide on its drug shortage list, allowing 503A compounding pharmacies (patient-specific) and 503B outsourcing facilities (larger-batch) to produce copies legally [8]. Many telehealth platforms began prescribing compounded semaglutide at $100 to $400 per month.

The FDA removed semaglutide from the shortage list in early 2025, triggering a phased enforcement action against compounders. As of mid-2025, 503A pharmacies may still compound for individual patients with a documented clinical need, but 503B facilities face stricter timelines [8]. Patients using compounded versions should verify their pharmacy's current 503A/503B status and ask their prescriber to document medical necessity.

Postpartum Eligibility: Who Actually Qualifies?

BMI and Comorbidity Thresholds

Both FDA labels require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity [1][3]. The American Association of Clinical Endocrinology (AACE) 2023 Obesity Algorithm states: "Pharmacotherapy is recommended as an adjunct to intensive lifestyle intervention in patients with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with at least one adiposity-related complication" [9].

Postpartum women often meet these criteria. Gestational weight retention of 5 kg or more at 6 months postpartum is reported in roughly 25% of pregnancies according to CDC data [10]. Retained weight frequently comes with new-onset insulin resistance, dyslipidemia, or elevated blood pressure, each of which satisfies the comorbidity threshold.

Timing After Delivery

Neither the Wegovy nor Zepbound label specifies a minimum postpartum interval, but standard clinical practice at most obesity medicine practices is to wait until breastfeeding has concluded. Semaglutide and tirzepatide have not been studied in lactating women, and both drugs carry warnings about unknown secretion in human milk [1][3]. Most prescribers apply a minimum 6-week postpartum window plus confirmed cessation of breastfeeding before initiating.

Lab and Baseline Requirements

A standard pre-treatment panel includes fasting glucose, HbA1c, a lipid panel, comprehensive metabolic panel, and TSH. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are contraindicated for both drugs due to rodent thyroid C-cell tumor findings, though the FDA label notes the human relevance is unknown [1].

What Insurance Actually Covers (and What It Does Not)

Commercial Insurance

Coverage varies sharply by employer plan. A 2023 KFF analysis found that fewer than half of large employer plans covered GLP-1 drugs specifically for weight loss (as opposed to type 2 diabetes), though that proportion has grown as employers weigh productivity data [11]. The Endocrine Society's clinical practice guideline recommends that "payers should cover anti-obesity medications as they cover medications for other chronic diseases" [12], but that recommendation has not yet translated into universal coverage.

Prior authorization is nearly universal for GLP-1 weight-loss prescriptions. Typical requirements include: documented BMI ≥30 (or ≥27 plus comorbidity), a 3-to-6-month record of supervised lifestyle intervention, and sometimes a step-therapy requirement through a cheaper drug first.

Medicare and Medicaid

Medicare Part D does not cover weight-loss drugs under the Social Security Act's exclusion for "agents when used for anorexia, weight loss, or weight gain." The Treat and Reduce Obesity Act, if passed, would remove that exclusion. Medicaid coverage is state-by-state; as of 2025, fewer than 15 states have added GLP-1 obesity coverage to their formularies.

The Practical Cost Scenarios

| Patient Type | Monthly Out-of-Pocket (Estimated) | |---|---| | Commercially insured, Wegovy covered | $0 with NovoCare coupon | | Commercially insured, Zepbound covered | $25 with Lilly Savings Card | | Uninsured, Zepbound vials (cash) | $349, $499 | | Uninsured, Wegovy (NovoCare uninsured program) | $500 | | Telehealth compounded semaglutide (503A, cash) | $100, $400 | | Medicare Part D beneficiary | Full list price or not covered |

The Telehealth Pathway: How Most Non-Celebrities Actually Get These Drugs

Most patients who access GLP-1 therapy for weight loss in 2024 and 2025 did so through a telehealth prescriber rather than a traditional in-person obesity medicine specialist. The pathway typically looks like this:

Step 1: Online intake. Patients complete a health history, upload a government ID and photo, and submit recent lab work or agree to lab draws ordered by the platform.

Step 2: Async or synchronous physician review. A licensed prescriber in the patient's state reviews the file. Approval for most straightforward cases takes 24 to 72 hours.

Step 3: Pharmacy routing. The prescriber routes to an in-network pharmacy. For branded drugs, that is usually a specialty mail-order pharmacy. For compounded versions, it is a partnered 503A or 503B facility.

Step 4: Titration management. Doses are adjusted monthly via messaging or video follow-up. Side effect management (nausea is the most common complaint, reported in 44% of STEP-1 semaglutide patients) is handled asynchronously in most platforms [2].

A celebrity with a concierge physician skips steps one through three entirely and receives a direct-ship prescription within 24 hours. The clinical outcome, assuming the same drug and dose, is identical. The difference is time, friction, and cost.

Side Effects and Monitoring: What the Trials Show

Gastrointestinal Events

Nausea, vomiting, diarrhea, and constipation are the most common adverse events with both drugs. In STEP-1, nausea occurred in 44.2% of semaglutide patients versus 16.0% placebo [2]. In SURMOUNT-1, nausea affected 31.0% of the tirzepatide 15 mg group versus 9.3% placebo [4]. Most events are mild-to-moderate and peak during dose escalation.

Serious but Rare Risks

Acute pancreatitis has been reported with GLP-1 agonists. The absolute rate in the STEP program was low (fewer than 1% of participants), but patients with a history of pancreatitis should discuss risk-benefit with their physician. Gallbladder disease, including cholelithiasis, occurred at a higher rate with semaglutide (2.6%) versus placebo (1.2%) in STEP-1 [2].

Muscle Mass Considerations

Rapid weight loss from any cause carries the risk of lean mass loss alongside fat mass. A 2023 study in Obesity (N=178) found that approximately 39% of weight lost on semaglutide was lean mass when resistance training was absent [13]. Clinicians at HealthRX routinely recommend a protein target of 1.2 to 1.6 g/kg of ideal body weight and structured resistance training at least twice weekly during GLP-1 therapy.

Cost-Reduction Strategies That Work in 2025

Use the Manufacturer Programs First

Both Novo Nordisk and Eli Lilly run patient assistance programs. Patients with commercial insurance should apply for the savings cards before filling the first prescription. The NovoCare program for Wegovy and the Zepbound Savings Card program are accessible directly through each manufacturer's website [5][6].

Appeal Insurance Denials

Initial prior authorization denials are not final. The AACE 2023 algorithm provides language clinicians can use in letters of medical necessity [9]. A documented comorbidity (even mild hypertension or pre-diabetes) strengthens an appeal significantly.

Ask About Lower-Dose Vials

Eli Lilly's single-dose vials of Zepbound are priced below the autoinjector pens and are available in 2.5 mg and 5 mg doses. For patients still in the titration phase, this may cut the first two months of cost by 50% to 65% [7].

Consider 90-Day Supplies

Some insurance plans reduce the per-unit cost when dispensing 90-day supplies through mail-order pharmacies. The savings can range from $50 to $150 per quarter depending on plan design.

A Note on "Celebrity Pricing" vs. Standard Pricing

The drugs themselves cost the same regardless of who is buying them at list price. What celebrities have is not a lower price; it is faster access, more attentive prescribers, and the financial buffer to absorb a $1,000-plus monthly bill without stress. A non-celebrity patient who qualifies clinically, uses manufacturer coupons, and works with a telehealth prescriber can reach the same drugs at $25 to $400 per month depending on insurance status. The clinical result, per the trial data, depends on adherence and dose, not on income.